OBJECTIVES: To describe the profile of patients with psoriasis who were treated with secukinumab, a newly approved biologic, in the U.S. and to examine secukinumab dosage use in real world practice. METHODS: Retrospective data from the Symphony Health Solutions Lx commercial claims database between July 1, 2013 and July 31, 2015 (study period) were included in the study. Adult patients (≥18 years) with at least one secukinumab claim during the study period and with ≥1 pharmacy or medical claim in the 12 months before (baseline period) their first secukinumab claim (index date) were selected. Patient demographics, insurance type and secukinumab dosage (estimated based on the days of supply and quantity) were examined as of the index date. Comorbidities and prior systemic therapies were identified during the baseline period. RESULTS: A total of 1,947 secukinumab patients were included, with a mean age of 49.8 years (standard deviation (SD): 12.6). 47.9% of the patients were female, 40.8% from the south, and 89.3% had commercial insurance. The mean modified Charlson Comorbidity Index (excluding psoriasis-related comorbidities) was 0.14 (SD: 0.5); the most prevalent comorbidities included hypertension (19.1%), hyperlipidemia (16.7%), and psoriatic arthritis (15.0%). Most patients (72.9%) received systemic treatments in the baseline period: 58.6% of patients used a biologic, with the most common being ustekinumab (27.3%) and adalimumab (21.7%); 34.0% of patients used a non-biologic, mostly methotrexate (19.9%); and 2.7% used phototherapy. The majority of patients (99.8%) initiated secukinumab on the 300mg dose. CONCLUSIONS: The most prevalent comorbidities among secukinumab patients included hypertension, hyperlipidemia and psoriatic arthritis. Many patients received previous treatment, with more than half using a biologic prior to secukinumab. Almost all patients used the 300mg dose.